Checkpoint Therapeutics (STU:CZTA) YoY EBITDA Growth : 78.72% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Checkpoint Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Checkpoint Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 78.72%.

Checkpoint Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.31.

Checkpoint Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Checkpoint Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Checkpoint Therapeutics YoY EBITDA Growth Chart

Checkpoint Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

43.98

46.09

-93.30

5.62

59.07

Checkpoint Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															20.11	37.82	70.31	80.04	78.72

Checkpoint Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Checkpoint Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-2.551	-	-6.232)	/	\| -6.232 \|
=	59.07 %

Checkpoint Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-0.306	-	-1.438)	/	\| -1.438 \|
=	78.72 %

Checkpoint Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Checkpoint Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Checkpoint Therapeutics (STU:CZTA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Checkpoint Therapeutics Inc (STU:CZTA) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

CKPT:USA

Address

95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453

Website

https://www.checkpointtx.com

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in us. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).

Checkpoint Therapeutics (STU:CZTA) Headlines

No Headlines